Jane Street Group LLC Invests $324,000 in Neurogene Inc. (NASDAQ:NGNE)

Jane Street Group LLC acquired a new stake in Neurogene Inc. (NASDAQ:NGNE) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 7,717 shares of the company’s stock, valued at approximately $324,000. Jane Street Group LLC owned approximately 0.06% of Neurogene as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NGNE. FMR LLC boosted its position in shares of Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after purchasing an additional 659,515 shares in the last quarter. Jennison Associates LLC acquired a new position in Neurogene during the 3rd quarter worth approximately $3,300,000. Integral Health Asset Management LLC bought a new position in Neurogene in the second quarter worth approximately $2,547,000. RTW Investments LP grew its stake in Neurogene by 6.0% in the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock valued at $47,635,000 after acquiring an additional 64,691 shares during the period. Finally, Driehaus Capital Management LLC increased its holdings in shares of Neurogene by 123.8% during the second quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after acquiring an additional 56,533 shares in the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

Wall Street Analysts Forecast Growth

NGNE has been the topic of a number of recent research reports. Stifel Nicolaus increased their target price on Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. William Blair reiterated an “outperform” rating on shares of Neurogene in a report on Tuesday, November 19th. BMO Capital Markets decreased their target price on shares of Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Robert W. Baird raised their price target on shares of Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Finally, Leerink Partners boosted their price objective on Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, November 12th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $60.83.

Neurogene Trading Down 1.7 %

NASDAQ:NGNE opened at $21.49 on Friday. Neurogene Inc. has a 52 week low of $14.44 and a 52 week high of $74.49. The firm has a 50-day moving average price of $29.61 and a two-hundred day moving average price of $36.86.

Insider Activity

In related news, major shareholder Samsara Biocapital Gp, Llc acquired 48,770 shares of the stock in a transaction on Tuesday, November 26th. The shares were acquired at an average price of $25.83 per share, with a total value of $1,259,729.10. Following the completion of the transaction, the insider now owns 1,717,127 shares in the company, valued at approximately $44,353,390.41. The trade was a 2.92 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christine Mikail Cvijic bought 24,000 shares of Neurogene stock in a transaction dated Friday, November 22nd. The shares were bought at an average cost of $20.48 per share, with a total value of $491,520.00. Following the completion of the transaction, the chief financial officer now directly owns 76,844 shares in the company, valued at approximately $1,573,765.12. This trade represents a 45.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 120,270 shares of company stock valued at $2,720,249 over the last three months. Corporate insiders own 9.92% of the company’s stock.

Neurogene Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.